Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models

There is a scarcity of drugs to either prevent or properly manage chemotherapy-induced neuropathic pain (CINP). Cannabis or cannabinoids have been reported to improve pain measures in patients with neuropathic pain. For this review, a search was done in PubMed for papers that examined the expression...

Full description

Saved in:
Bibliographic Details
Main Author: Willias Masocha
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2018/5234943
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832568071352483840
author Willias Masocha
author_facet Willias Masocha
author_sort Willias Masocha
collection DOAJ
description There is a scarcity of drugs to either prevent or properly manage chemotherapy-induced neuropathic pain (CINP). Cannabis or cannabinoids have been reported to improve pain measures in patients with neuropathic pain. For this review, a search was done in PubMed for papers that examined the expression of and/or evaluated the use of cannabinoids or drugs that prevent or treat established CINP in a CB receptor-dependent manner in animal models. Twenty-eight articles that fulfilled the inclusion and exclusion criteria established were analysed. Studies suggest there is a specific deficiency of endocannabinoids in the periphery during CINP. Inhibitors of FAAH and MGL, enzymes that degrade the endocannabinoids, CB receptor agonists, desipramine, and coadministered indomethacin plus minocycline were found to either prevent the development and/or attenuate established CINP in a CB receptor-dependent manner. The studies analysed suggest that targeting the endocannabinoid system for prevention and treatment of CINP is a plausible therapeutic option. Almost 90% of the studies on animal models of CINP analysed utilised male rodents. Taking into consideration clinical and experimental findings that show gender differences in the mechanisms involved in pain including CINP and in response to analgesics, it is imperative that future studies on CINP utilise more female models.
format Article
id doaj-art-4ad4ee1e9d894ea096f37a5351068dcd
institution Kabale University
issn 1203-6765
1918-1523
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series Pain Research and Management
spelling doaj-art-4ad4ee1e9d894ea096f37a5351068dcd2025-02-03T00:59:50ZengWileyPain Research and Management1203-67651918-15232018-01-01201810.1155/2018/52349435234943Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal ModelsWillias Masocha0Department of Pharmacology and Therapeutics, Faculty of Pharmacy, Kuwait University, Safat 13110, KuwaitThere is a scarcity of drugs to either prevent or properly manage chemotherapy-induced neuropathic pain (CINP). Cannabis or cannabinoids have been reported to improve pain measures in patients with neuropathic pain. For this review, a search was done in PubMed for papers that examined the expression of and/or evaluated the use of cannabinoids or drugs that prevent or treat established CINP in a CB receptor-dependent manner in animal models. Twenty-eight articles that fulfilled the inclusion and exclusion criteria established were analysed. Studies suggest there is a specific deficiency of endocannabinoids in the periphery during CINP. Inhibitors of FAAH and MGL, enzymes that degrade the endocannabinoids, CB receptor agonists, desipramine, and coadministered indomethacin plus minocycline were found to either prevent the development and/or attenuate established CINP in a CB receptor-dependent manner. The studies analysed suggest that targeting the endocannabinoid system for prevention and treatment of CINP is a plausible therapeutic option. Almost 90% of the studies on animal models of CINP analysed utilised male rodents. Taking into consideration clinical and experimental findings that show gender differences in the mechanisms involved in pain including CINP and in response to analgesics, it is imperative that future studies on CINP utilise more female models.http://dx.doi.org/10.1155/2018/5234943
spellingShingle Willias Masocha
Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
Pain Research and Management
title Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
title_full Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
title_fullStr Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
title_full_unstemmed Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
title_short Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models
title_sort targeting the endocannabinoid system for prevention or treatment of chemotherapy induced neuropathic pain studies in animal models
url http://dx.doi.org/10.1155/2018/5234943
work_keys_str_mv AT williasmasocha targetingtheendocannabinoidsystemforpreventionortreatmentofchemotherapyinducedneuropathicpainstudiesinanimalmodels